On Dec. 19, Congress passed a year-end spending bill that included the Laboratory Access for Beneficiaries (LAB) Act. The bill went to the President for his signature. The bill mandates that the federal Centers or Medicare and Medicaid Services (CMS) delay by one year having labs report their private payer lab test data. This means no
WHEN AN ANATOMIC PATHOLOGY GROUP CONSIDERS IMPLEMENTING digital pathology and whole-slide imaging (WSI) for primary diagnosis, it must identify and understand a range of challenges and opportunities.
“Every pathology group should start by considering how it will use the related technologies of a digital pathology (DP) system and whole-slide imaging,” said Liron Pantanowitz, MD, Vice Chair
CEO SUMMARY: Among hospital administrators, the popular wisdom is that their clinical lab is a cost center. This thinking leads them to consider drastic cost-management strategies that include partnering with commercial labs to manage in-hospital lab testing and the outright sale of lab outreach programs. On the other side of this debate, innovative health system
IN TWO COUNTRIES, regulators concerned about a possible monopoly of technologies and instruments used in human gene sequencing apparently were a major reason why the $1.2 billion acquisition of Pacific Biosciences by Illumina Corporation will not happen.
The two companies announced the termination of the transaction just weeks after the Federal Trade Commission (FTC) ruled the deal
CEO SUMMARY: In a federal lawsuit against Laboratory Corporation of America, plaintiffs who were uninsured or underinsured charged the lab company with engaging in “business practices that trick and harass customers into paying excessive prices.” Plaintiffs made this and other claims in court documents alleging that LabCorp overcharged them by two to five and as
CEO SUMMARY: When CMS and the OIG issued proposed rules last fall to make it easier for providers to participate in value-based and coordinated care arrangements, they considered excluding clinical labs, pharma companies, and DME firms because of concerns that the proposed rules could promote lab test fraud. Now, labs will have to wait for
TYPICALLY, PEOPLE CELEBRATE THE ARRIVAL OF A NEW YEAR and a new decade with optimism. That should be just as true for clinical lab managers and pathologists. After all, medical laboratory testing is fundamental to how physicians diagnose disease, select the most appropriate therapies, and monitor the progress of their patients.
Yet events of recent years have
Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.
